Edition:
India

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

6.43USD
15 Dec 2017
Change (% chg)

$-0.27 (-4.03%)
Prev Close
$6.70
Open
$6.63
Day's High
$6.80
Day's Low
$6.28
Volume
6,828,921
Avg. Vol
864,305
52-wk High
$8.84
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

ImmunoGen reports Q3 loss per share $0.61
Friday, 3 Nov 2017 

Nov 3 (Reuters) - ImmunoGen Inc :ImmunoGen reports recent progress and third quarter 2017 operating results.Q3 loss per share $0.61.Q3 revenue $8.5 million versus $7.7 million.Q3 revenue view $33.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.ImmunoGen Inc - ‍Has updated its guidance for 2017​.Revenue guidance remains unchanged and is expected to be between $115 million and $120 million.ImmunoGen Inc - ‍Cash and cash equivalents at December 31, 2017 are expected to be between $260 million and $265 million​.ImmunoGen- Operating expenses for 2017 are now expected to be between $170 and $175 million, compared to previous guidance of $175 to $180 million.ImmunoGen - Expects current cash combined with expected cash revenue from partners & collaborators will enable co to fund operations into Q4 2019​.  Full Article

Immunogen prices offering of 14.5 mln common shares at $6.50 per share
Friday, 6 Oct 2017 

Oct 5 (Reuters) - Immunogen Inc :Immunogen announces pricing of public offering of common stock.Says public offering of 14.5 million common shares priced at $6.50 per share.  Full Article

ImmunoGen intends to offer and sell 13 mln shares of common stock​
Thursday, 5 Oct 2017 

Oct 4 (Reuters) - ImmunoGen Inc :ImmunoGen announces proposed public offering of common stock.ImmunoGen Inc - intends to offer and sell 13 million shares of its common stock​.  Full Article

Immunogen: Will reduce workforce by 17 pct
Friday, 30 Sep 2016 

Immunogen Inc : Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs . Through this plan, Immunogen will realize significant cost savings over next two years in headcount, program, and support activities . These savings will include approximately $11 million per year relating to elimination of 65 positions . Expects to achieve previously-stated goal of funding operations through analysis of mirvetuximab soravtansine pivotal trial,into mid-2018 . As a result of workforce reduction, immunogen will record a one-time charge totaling approximately $3.5 million .As part of this effort and prioritization of its ign programs, will seek to monetize its non-core b-cell assets through partnering with interested parties.  Full Article

Immunogen announces update to financial results year ended June 30, 2016 - SEC filing
Friday, 26 Aug 2016 

Immunogen Inc: Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing . Due to info that became available related to potential liability to a contract manufacturer, additional expense accrual was required . Due to the additional expense accrual, financial results have been adjusted .FY net loss increased to $144.8 million or $1.67 per share, will be reported as such in 10-K filing.  Full Article

Immunogen Q4 loss per share $0.51
Thursday, 4 Aug 2016 

Immunogen Inc : Q4 loss per share $0.51 . Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update . Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Phase 3 forward I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end. . Ended fiscal year with approximately $245 million in cash . For six months ending December 31, 2016, Immunogen expects revenues to be between $40 million and $45 million .For six months ending December 31, 2016, Immunogen expects net loss to be between $55 million and $60 million.  Full Article

ImmunoGen announces pricing of $100 mln offering of Senior Notes
Wednesday, 15 Jun 2016 

Immunogen Inc : Sale of notes is expected to result in $96.7 million net proceeds to Immunogen . Interest will be payable semi-annually in arrears on january 1 and july 1 of each year, beginning january 1, 2017 . Sale of notes expected to result in proceeds of $111.2 million if initial purchasers exercise option to purchase additional notes in full . Notes will be senior unsecured obligations of Immunogen, and will bear interest at a rate of 4.50% per year .Immunogen announces pricing of $100 million offering of 4.50% convertible senior notes due 2021.  Full Article

Immunogen announces proposed $100 mln offering of convertible senior notes
Tuesday, 14 Jun 2016 

Immunogen Inc : Immunogen announces proposed $100 million offering of convertible senior notes due 2021 . Says notes will be senior unsecured obligations of immunogen, and interest will be payable semi-annually .Immunogen Inc says intends to use net proceeds of offering for its operations, including but not limited to clinical trial expenditures.  Full Article

ImmunoGen reports positive early-stage data on ovarian cancer drug
Thursday, 19 May 2016 

Immunogen : Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in frα-positive ovarian cancer . Company preparing to meet with FDA in early 3q 2016; targeting initiation of phase 3 study in 4q2016 .Plan to have phase 3 testing of mirvetuximab soravtansine up and running by year end.  Full Article

ImmunoGen Inc Updates FY 2016 guidance
Friday, 29 Apr 2016 

ImmunoGen Inc:Updated its guidance for FY 2016.Expected FY 2016 revenues are now projected to be between $60 million and $70 million, compared with previous guidance of between $70 million and $80 million.Guidance for FY 2016 net loss is now expected to be between $135 million and $140 million, compared to its previous estimate of $120 million and $125 million with most of this change being non-cash related.  Full Article

BRIEF-ImmunoGen reports Q3 loss per share $0.61

* ImmunoGen reports recent progress and third quarter 2017 operating results